Chitosan-Based Polyelectrolyte Complexes as Potential Nanoparticulate Carriers: Physicochemical and Biological Characterization

Ramasamy, Thiruganesh; Tran, Tuan Hiep; Cho, Hyuk Jun; Kim, Jeong Hwan; Kim, Yong Il; Jeon, Jae Yoon; Choi, Han‐Gon; Yong, Chul Soon; Kim, Jong Oh

doi:10.1007/s11095-013-1251-9

Cited by 85 publications

(42 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By increasing DOX concentration from 80 to 154 µg/ml, the DOX 333 EE% decreased from 66.50% ± 2.68 to 51.09% ± 2.88. Similar results were found elsewhere 334 [17,18,52], pointing out that a larger amount of drug does not mean any increase in 335 encapsulation efficiency. As a limited number of functional groups is available for electrostatic 336 interactions with the drug in the NP matrix, the increase in the amount of drug added to the 337 formulation could have resulted in a decrease in drug entrapment efficiency.…”

Section: Characterization and Ee% Of Nanoparticles 307supporting

confidence: 87%

“…CS is widely regarded as being a non-toxic and biologically 259 The process to prepare the NPs was optimized to be simple and fast. Firstly, positive 285 charges (DOX and CS) were mixed [5,17] and, a premixed solution of the negatively charged 286 compounds (TPP and 77KS) was added drop-wise, leading to spontaneous formation of the 287 colloidal system. It is known that the polyanion TPP has multiple charged functional groups, 288 which makes it able to interact with both DOX and CS, resulting in shielding and electrostatic 289 interactions [17].…”

Section: Results and Discussion 255mentioning

confidence: 99%

“…Firstly, positive 285 charges (DOX and CS) were mixed [5,17] and, a premixed solution of the negatively charged 286 compounds (TPP and 77KS) was added drop-wise, leading to spontaneous formation of the 287 colloidal system. It is known that the polyanion TPP has multiple charged functional groups, 288 which makes it able to interact with both DOX and CS, resulting in shielding and electrostatic 289 interactions [17]. The pH of CS solution was set at 5.5, in which about 90% of the amino groups 290 of CS (pKa = 6.5) are protonated [45].…”

Section: Results and Discussion 255mentioning

confidence: 99%

“…It is worth mentioning that besides the swelling mechanism of CS, DOX may have an 392 improved solubility and, TPP, a reduced ionization in acidic environments [17,57]. This later 393 condition may result in NP network destabilization and thus faster drug delivery, which could 394 be the basis for the pH-responsive drug release observed for the NPs without 77KS (Fig.…”

Section: In Vitro Dox Release 347mentioning

confidence: 99%

“…Chitosan has been widely used for the development of DOX-loaded NPs by simple and mild 72 preparation techniques [5,[16][17][18]. CS-NPs modified by polyethylene glycol (PEG) are explored 73 due to the ability of this hydrophilic polymer to prolong the circulation time of nanocarriers in 74 the blood stream.…”

Section: Introduction 51mentioning

confidence: 99%

See 4 more Smart Citations

PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release

Scheeren

Nogueira

Macedo

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

28The growing demand for efficient chemotherapy in many cancers requires novel approaches in 29 target-delivery technologies. Nanomaterials with pH-responsive behavior appear to have 30 potential ability to selectively release the encapsulated molecules by sensing the acidic tumor 31 microenvironment or the low pH found in endosomes. Likewise, polyethylene glycol (PEG)-32 and poloxamer-modified nanocarriers have been gaining attention regarding their potential to 33 improve the effectiveness of cancer therapy. In this context, DOX-loaded pH-responsive 34 nanoparticles (NPs) modified with PEG or poloxamer were prepared and the effects of these 35 modifiers were evaluated on the overall characteristics of these nanostructures. Chitosan and 36 tripolyphosphate were selected to form NPs by the interaction of oppositely charged 37 compounds. A pH-sensitive lysine-based amphiphile (77KS) was used as a bioactive adjuvant. 38The strong dependence of 77KS ionization with pH makes this compound an interesting 39 candidate to be used for the design of pH-sensitive devices. The physicochemical 40 characterization of all NPs has been performed, and it was shown that the presence of 77KS 41 clearly promotes a pH-triggered DOX release. Accelerated and continuous release patterns of 42 DOX from CS-NPs under acidic conditions were observed regardless of the presence of PEG 43 or poloxamer. Moreover, photodegradation studies have indicated that the lyophilization of NPs 44 improved DOX stability under UVA radiation. Finally, cytotoxicity experiments have shown 45 the ability of DOX-loaded CS-NPs to kill HeLa tumor cells. Hence, the overall results suggest 46 that these pH-responsive CS-NPs are highly potent delivery systems to target tumor and 47 intracellular environments, rendering them promising DOX carrier systems for cancer therapy. 48 Keywords: chitosan nanoparticles; doxorubicin; in vitro release; in vitro cytotoxicity; lysine-49 based surfactant; pH-sensitivity 50

show abstract

Section: Characterization and Ee% Of Nanoparticles 307supporting

confidence: 87%

Section: Results and Discussion 255mentioning

confidence: 99%

Section: Results and Discussion 255mentioning

confidence: 99%

Section: In Vitro Dox Release 347mentioning

confidence: 99%

Section: Introduction 51mentioning

confidence: 99%

See 3 more Smart Citations

PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release

Scheeren

Nogueira

Macedo

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

Marine‐origin Polysaccharides for Tissue Engineering and Regenerative Medicine

Reys

Silva

Oliveira

et al. 2020

Encyclopedia of Marine Biotechnology

View full text Add to dashboard Cite

Mixed Micelles for Targeted and Efficient Doxorubicin Delivery to Multidrug‐Resistant Breast Cancer Cells

Jung

Mok

2016

Macromolecular Bioscience

View full text Add to dashboard Cite

For efficient treatment of multidrug-resistance (MDR) breast cancer cells, design of biocompatible mixed micelles with diverse functional moieties and superior stability is needed for targeted delivery of chemical drugs. In this study, polypropylene glycol (PPG)-grafted hyaluronic acid (HA) copolymers (PPG-g-HA) are used to make mixed micelles with different amounts of pluronic L61, named PPG-g-HA/L61 micelles. Optimized PPG-g-HA/L61 micelles with 3% pluronic L61 exhibit great stability in aqueous solution, superior biocompatibility, and significantly increased uptake into MCF-7 MDR cells via HA-CD44-specific interactions when compared to free doxorubicin (DOX) and other types of micelles. In addition, DOX in PPG-g-HA/L61 micelles with 3% pluronic L61 have toxicity in MCF-7 MDR cells but significantly lower toxicity in fibroblast L929 cells compared to free DOX. Thus, PPG-g-HA/L61 micelles with 3% pluronic L61 content can be a promising nanocarrier to overcome MDR and release DOX in a hyaluronidase-sensitive manner without any toxicity to normal cells.

show abstract

Chitosan-Based Polyelectrolyte Complexes as Potential Nanoparticulate Carriers: Physicochemical and Biological Characterization

Abstract: Taken together, CS-based polyelectrolyte complexes could provide a versatile delivery system with enormous potential in the pharmaceutical and biomedical sectors.

Cited by 85 publications

References 42 publications

PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release

PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release

Marine‐origin Polysaccharides for Tissue Engineering and Regenerative Medicine

Mixed Micelles for Targeted and Efficient Doxorubicin Delivery to Multidrug‐Resistant Breast Cancer Cells

Contact Info

Product

Resources

About